Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Axogen, Inc. - Common Stock (NQ:AXGN)

37.39 -2.53 (-6.34%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Axogen, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen Announces Pricing of Upsized $124 Million Public Offering of Common Stock
From Axogen, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For October 29, 2025 ↗
 
Via Benzinga
News headline image
Axogen Announces Proposed Public Offering of Common Stock
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen CEO Axed 25,000 Shares From His Direct Holdings ↗
The CEO of this innovative nerve regeneration company sold thousands of shares in December 2025, among multiple other insiders at the company who sold shares to close out that year. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen, Inc. to Participate in the J.P. Morgan 2026 Healthcare Conference
From Axogen, Inc.
Via GlobeNewswire
News headline image
Gapping stocks in Thursday's session ↗
The market is buzzing with gapping stocks on Thursday. Let's uncover which stocks are experiencing notable gaps during today's session. 
Via Chartmill
News headline image
AXGN Stock Rises Pre-Market After FDA Approves Nerve Repair Graft ↗
Axogen’s Avance is an acellular nerve scaffold for the treatment of adult and pediatric patients aged a month or older with sensory, mixed, and motor peripheral nerve discontinuities. 
Via Stocktwits
Topics Government
News headline image
Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx)
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences
From Axogen, Inc.
Via GlobeNewswire
News headline image
Keep an eye on the top gainers and losers in Wednesday's session. ↗
Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Caterpillar Posts Upbeat Q3 Results, Joins United Therapeutics, Centene, Fortive And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
Axogen Inc (NASDAQ:AXGN) Surges on Strong Q3 2025 Earnings Beat and Raised Guidance ↗
Axogen (AXGN) stock surged after Q3 2025 earnings beat estimates. Revenue grew 23.5% to $60.1M, while adjusted EPS of $0.12 crushed forecasts. The company also raised its full-year guidance. 
Via Chartmill
Topics Earnings
News headline image
Axogen, Inc. Reports Third Quarter 2025 Financial Results
Raises Full Year Revenue Guidance to at Least 19% Growth or $222.8 million 
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen, Inc. to Report 2025 Third Quarter Financial Results on October 29, 2025
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – AXGN
From DJS Law Group
Via Business Wire
News headline image
AXGN Investors Have Opportunity to Join Axogen, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN
From Pomerantz LLP
Via GlobeNewswire
News headline image
Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences
From Axogen, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Keurig Dr Pepper, Valneva, Venu Holding And Other Big Stocks Moving Lower On Monday ↗
 
Via Benzinga
News headline image
FDA Pushes Back Axogen Avance Nerve Graft Decision By 3 Months ↗
FDA delays Axogen's Avance Nerve Graft BLA review to December 5, after new data submission, while the company raises its full-year revenue outlook. 
Via Benzinga
News headline image
Why Axogen Stock, Up 76% Over The Last Two Months, Just Plummeted ↗
The FDA's move is largely procedural, says one analyst, but it adds incremental uncertainty. 
Via Investor's Business Daily
News headline image
Which stocks are moving before the opening bell on Monday? ↗
Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.